WO1997019593A1 - Antimicrobial composition and methods of use therefor - Google Patents
Antimicrobial composition and methods of use thereforInfo
- Publication number
- WO1997019593A1 WO1997019593A1 PCT/US1996/018899 US9618899W WO9719593A1 WO 1997019593 A1 WO1997019593 A1 WO 1997019593A1 US 9618899 W US9618899 W US 9618899W WO 9719593 A1 WO9719593 A1 WO 9719593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- acid
- hydrotrope
- fatty acid
- pylori
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention pertains to antimicrobial compositions. Even more particularly the present invention concerns the use of antimicrobial compositions and the treatment of gastritis. Most particularly, the present invention concerns the use of food grade components m antimicrobial compositions for the treatment of gastritis.
- H. pylori the gram negative bacterium H. pylori
- campylobacter pyloridis is the cause of gastric and duodenal ulceration associated with chronic gastritis.
- individuals infected with H. pylori have been observed to have an increased rate of gastric cancer. Therefore, a simple efficacious manner of eliminating this bacterium from the system would be more advantageous.
- H. pylori is found at the epithelial cell junctions beneath the mucus layer of the stomach and is, therefore, thought to be effectively killed by systemic exposure to antibiotics as well as by direct lummal contact, thus, curing gastric and duodenal ulceration and decreasing the incidence of recurrence. Because of the observed and potential development of antibiotic resistant strains of H. pylori and the difficulty of penetrating the hydrophobic gastric mucus, coupled with the observed failure or ineffectiveness of single antibiotic therapy, the combination of 2 or 3 antibiotics is typically used.
- the present invention provides a simple inexpensive way of treating H. pylori.
- composition for arresting or eliminating H. pylori bacteria which, generally, comprises:
- each of the components used in the composition are "food grade” or have 4
- the composition hereof has a pH ranging from about 1 to about 5.
- a method for arresting or eliminating H. pylori bacteria from the body of the user which, generally, comprises contacting the H. pylori bacteria with the antimicrobial composition hereof. Contacting the bacterium with the composition is achieved by ingesting or otherwise introducing the composition into the digestive tract of the user.
- composition may be ingested either as a liquid, as a gelatinized capsule or may be introduced by any other suitable medium which permits the introduction of the composition into the body of the user.
- the present invention relates to the use of sanitizing and disinfecting compositions of matter to eliminate infestations of the gastrointestinal tract by microorganisms.
- these infestations range from colonic infections with pathogenic microorganisms including bacteria, yeast, fungi, ⁇ ckettsia and the like to intestinal and gastric overgrowth with pathogenic and nonpathogenic microorganisms.
- the invention is particularly directed to the treatment of gastritis and related ulceration of the stomach and duodenum caused by bacterium Helicobacter pylori (hereinafter H. pylori) .
- compositions of matter or disinfectant active agents with low toxicity will essentially eliminate the risk associated with antibiotic treatment, allowing prophylactic treatment.
- an antimicrobial composition for the elimination of H. pylori which, generally, comprises:
- a vehicle or transport medium for the composition wherein the components are "food grade” or have low toxicity levels to permit ingestion or can otherwise can be introduced internally into the body of the user.
- composition hereof has a pH ranging from about 1 to about 5 and, preferably ranges from about 2.5 to about 3.5.
- composition hereof can be prepared as a concentrate which can, then, be diluted with water or other diluent for usage.
- the composition can be prepared directly as a use composition such as m a gelatinized capsule, as a tablet, etc.
- the Antimicrobial Active Agent contemplated for use herein is, preferably, a food grade, aliphatic or aromatic fatty acid, either saturated or unsaturated, preferably, saturated, and having from about 6 to about 20 carbon atoms and, preferably, from about 8 to about 12 carbon atoms, as well as mixtures thereof.
- the fatty acid may be linear, branched or cyclic and may contain substituent atoms such as hydroxyl groups or ether linkages as long as the substituents do not affect antimicrobial activity.
- the fatty acids employed is food grade, linear, saturated and unsubstituted.
- Representative of the fatty acids contemplated for use herein include caproic acid, caprylic acid, capric acid and lauric acid, as well as mixtures thereof.
- a particularly preferred fatty acid is caprylic acid.
- hydrotrope or solubilizmg agent or solubilizer is employed to enhance the stability or antimicrobial activity or penetration of the mucosal layer by the fatty acid.
- the antimicrobial action of short chain fatty acids is significantly greater in the protonated state.
- undissociated fatty acids have negligible solubility m water.
- the solubilizer brings the fatty ac ⁇ d(s) into aqueous solution, either when diluted into the use solution or by the gastric juices.
- Hydroptropes or solubilizers for fatty acids are well known the art.
- the preferred solubilizer is non-toxic and retains fatty acids m aqueous solution m the use solution.
- Preferred solubilizers for use herein include anionic surfactants such as alkylphosphates or phosphonates, sugar esters, alkyl glycosides, alkyl sulfates, alkane sulfonates, alpha olefin sulfonates, linear alkyl benzene or napthalene sulfonates, secondary alkane sulfonates, alkyl ether sulfates or sulfonates and diaklylsulfosuccmic acid esters as well as mixtures thereof.
- the preferred solubilizer for use herein is food grade, sodium lauryl sulfate.
- solubilizer besides hydrotropmg the fatty acids into solution, also, disrupts the gastric mucus allowing exposure of infecting organisms to the disinfectant in the lumen of the stomach or intestines, since the gastric mucus is known to be hydrophobic and to be disrupted by solubilizmg agents such as hydrotropes and surfactants.
- the disinfectant composition requires the presence of a hydrotrope compatible acid in sufficient concentration to provide a pH m the range of about 1 to about 5, and preferably from about 2.5 to about 3.5, when the use composition is diluted by gastric secretions.
- the selected acid should be compatible with product stability and not cause the chemical degradation of the hydrotrope.
- the acid is, generally, a weak, food grade, organic acid such as but not limited to citric acid, acetic acid, fumaric acid and maleic acid and the like as well as mixtures thereof. Mineral acids will produce the same effect but are more difficult to formulate in an ingestible form. Organic acids are generally preferred, especially when sulfated or sulfonated hydrotropes are used due to their instability mineral acids. Food grade, citric acid is preferred. Citric acid provides added antimicrobial effects since citric acid is known in the art to be biocidal.
- the preferred vehicle, where used, is water. However, it is not essential hereto.
- the disinfectant composition of the present invention can be formulated in a concentrate without the addition of water or other optional agents.
- composition may include flavoring agents, gums, colorants, sweeteners or salts as approved for use in medications and foods by the United States Food and Drug Administration in the Code of Federal Regulations.
- the composition hereof In preparing the composition hereof, generally, it is prepared as a liquid concentrate by admixing the components together at ambient temperature. Generally, the concentrate will comprise from about 0.1% to about 15% by weight of the fatty acid based on the total weight, from about 0.1% to about 30%, by weight of the hydrotrope based on the total weight, from about 0.1% to about 50% by weight of the hydrotrope compatible acid based on the total weight, the balance being the vehicle as well as any other components.
- the composition is diluted with water or other suitable fluid m which the concentrate is stable.
- the diluent is water.
- the use solution will contain, by weight, from about 0.1% to about 10% of concentrate, with the balance being diluent.
- This example illustrates the preparation of an antimicrobial composition in accordance herewith.
- the concentrate has a pH of about 3.3 and is a water white liquid.
- the concentrate is, then, diluted with water a 1:20 weight ratio to provide the use composition.
- the resulting composition has a pH of about 3.5.
- This example illustrates the utilization of the antimicrobial composition of the present invention.
- composition of Example I is orally administered by admixing 5 parts (by volume) of the composition of Example I with approximately 100 parts of cold tap water to provide a "dose" thereof. This dose is taken three times per day. The first dose is taken followmg an approximate ten hour fast and at least 30 minutes prior to ingesting any food or drink. Subsequent doses are taken approximate 30 minutes before meals.
- the final dosage form of the composition is a 0.25 part antimicrobial fatty acid, a 0.25 part surfactant and 0.25 part acid, based on a 5 part dose.
- the present invention is contemplated as either a concentrated solution for dilution into a suitable vehicle for oral administration or a ready to use solution. However, it may be encapsulated or incorporated into other solid forms such as a gel, a time release capsule and the like known the medicinal arts.
- the disinfectant compositions of the present invention meet the need for elimination of pathogenic organisms from the gastrointestinal tract of animals and human by direct, lummal contact with bactericidal and fungicidal agents, avoiding the use of antibiotics. Further, since the disinfectant and sanitizing compositions hereof employ only food grade compositions of matter, concerns over potential toxicity is eliminated.
- the present invention allows prophylactic treatment of patients presenting with chronic gastritis prior to the development of gastric or duodenal ulcers without expensive and frequently invasive testing due to the absence of risk m relation to toxicity.
- the present invention provides for the arresting of H. pylori bacteria by the contacting thereof with an antimicrobial compound at levels safe for ingestion.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/077,148 US6071961A (en) | 1995-11-28 | 1996-11-25 | Antimicrobial composition and methods of use therefor |
JP52060597A JP2001509779A (en) | 1995-11-28 | 1996-11-25 | Antimicrobial compositions and methods of use |
EP96942811A EP0914040A1 (en) | 1995-11-28 | 1996-11-25 | Antimicrobial composition and methods of use therefor |
AU11412/97A AU721868B2 (en) | 1995-11-28 | 1996-11-25 | Antimicrobial composition and methods of use therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1461795P | 1995-11-28 | 1995-11-28 | |
US60/014,617 | 1995-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997019593A1 true WO1997019593A1 (en) | 1997-06-05 |
Family
ID=21766577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/018899 WO1997019593A1 (en) | 1995-11-28 | 1996-11-25 | Antimicrobial composition and methods of use therefor |
Country Status (7)
Country | Link |
---|---|
US (1) | US6071961A (en) |
EP (1) | EP0914040A1 (en) |
JP (1) | JP2001509779A (en) |
AU (1) | AU721868B2 (en) |
CA (1) | CA2238484A1 (en) |
MX (1) | MX9804139A (en) |
WO (1) | WO1997019593A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002015844A2 (en) * | 2000-08-23 | 2002-02-28 | Wider Michael D | Antimicrobial composition and methods of use in the treatment of disease |
JP2009179639A (en) * | 2001-05-03 | 2009-08-13 | Oligos Etc Inc | Antimicrobial compound and method for their use |
CN102088984B (en) * | 2008-07-11 | 2012-08-22 | 万灵杀菌消毒剂股份有限公司 | Eradicating agent and eradication method for helicobacter pylori |
US8435960B2 (en) | 1998-12-30 | 2013-05-07 | Lakewood-Amedex, Inc. | Devices for improved wound management |
CN108300680A (en) * | 2018-04-18 | 2018-07-20 | 深圳市伯劳特生物制品有限公司 | Helicobacter pylori transports culture medium |
EP3797761A1 (en) * | 2019-09-27 | 2021-03-31 | Eco-Geo Bio-Technology Company Limited | Non-pharmaceutical bactericidal composition against helicobacter pylori |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2810547B1 (en) * | 2000-06-22 | 2004-01-30 | Pasteur Institut | USE OF C2-C10 ACIDS FOR THE PREVENTION OF NEGATIVE GRAM BACTERIA INFECTIONS |
US6610314B2 (en) | 2001-03-12 | 2003-08-26 | Kimberly-Clark Worldwide, Inc. | Antimicrobial formulations |
US20040001797A1 (en) * | 2002-06-21 | 2004-01-01 | Abel Saud | Antimicrobial compositions, products and methods employing same |
US7569530B1 (en) * | 2003-06-20 | 2009-08-04 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
NZ534007A (en) | 2004-07-09 | 2007-06-29 | Horticulture & Food Res Inst | Fungicidal composition comprising anhydrous milk fat (AMF) and soybean oil for the treatment of Powdery Mildew |
US20070166341A1 (en) * | 2005-07-12 | 2007-07-19 | Tetsuo Nakatsu | Solid volatile composition and method and system for making the same |
US11028348B2 (en) | 2014-10-09 | 2021-06-08 | ProNatural Brands, LLC | Naturally-derived antimicrobial cleaning solutions |
US10076115B2 (en) | 2014-10-09 | 2018-09-18 | ProNatural Brands, LLC | Naturally-derived surface sanitizer and disinfectant |
US10772343B2 (en) | 2014-11-19 | 2020-09-15 | Kansas State University Research Foundation | Chemical mitigants in animal feed and feed ingredients |
WO2018076074A1 (en) * | 2016-10-31 | 2018-05-03 | Suda Ltd | Mucosal active agent delivery |
CN112569225B (en) * | 2019-09-27 | 2022-10-21 | 共生地球生物科技有限公司 | Non-drug helicobacter pylori bactericidal composition |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4404040A (en) * | 1981-07-01 | 1983-09-13 | Economics Laboratory, Inc. | Short chain fatty acid sanitizing composition and methods |
US4975217A (en) * | 1981-07-20 | 1990-12-04 | Kimberly-Clark Corporation | Virucidal composition, the method of use and the product therefor |
US5208257A (en) * | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
US5280042A (en) * | 1990-11-28 | 1994-01-18 | Microcide, Inc. | Disinfecting and sanitizing compositions |
WO1994010837A1 (en) * | 1992-11-09 | 1994-05-26 | West Agro, Inc. | Improved acid sanitizer composition |
US5460833A (en) * | 1993-09-14 | 1995-10-24 | Minnesota Mining And Manufacturing Company | Disinfectant composition |
WO1995031956A1 (en) * | 1994-05-20 | 1995-11-30 | Novavax, Inc. | Antibacterial oil-in-water emulsions |
WO1995034554A1 (en) * | 1994-06-10 | 1995-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria |
-
1996
- 1996-11-25 CA CA002238484A patent/CA2238484A1/en not_active Abandoned
- 1996-11-25 AU AU11412/97A patent/AU721868B2/en not_active Ceased
- 1996-11-25 WO PCT/US1996/018899 patent/WO1997019593A1/en not_active Application Discontinuation
- 1996-11-25 JP JP52060597A patent/JP2001509779A/en active Pending
- 1996-11-25 EP EP96942811A patent/EP0914040A1/en not_active Withdrawn
- 1996-11-25 US US09/077,148 patent/US6071961A/en not_active Expired - Fee Related
-
1998
- 1998-05-25 MX MX9804139A patent/MX9804139A/en not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4404040A (en) * | 1981-07-01 | 1983-09-13 | Economics Laboratory, Inc. | Short chain fatty acid sanitizing composition and methods |
US4404040B1 (en) * | 1981-07-01 | 1989-03-07 | ||
US4975217A (en) * | 1981-07-20 | 1990-12-04 | Kimberly-Clark Corporation | Virucidal composition, the method of use and the product therefor |
US5208257A (en) * | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
US5280042A (en) * | 1990-11-28 | 1994-01-18 | Microcide, Inc. | Disinfecting and sanitizing compositions |
WO1994010837A1 (en) * | 1992-11-09 | 1994-05-26 | West Agro, Inc. | Improved acid sanitizer composition |
US5460833A (en) * | 1993-09-14 | 1995-10-24 | Minnesota Mining And Manufacturing Company | Disinfectant composition |
WO1995031956A1 (en) * | 1994-05-20 | 1995-11-30 | Novavax, Inc. | Antibacterial oil-in-water emulsions |
WO1995034554A1 (en) * | 1994-06-10 | 1995-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria |
Non-Patent Citations (2)
Title |
---|
PHARMAZIE, Vol. 46, 1991, JAIN et al., "Hydrotropoic Solubilzation of Nalidixic Acid", pages 798-800. * |
THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 333, No. 15, 12 October 1995, WOOD et al., "The Treatment of Helicobacter Pylori Infection in the Management of Peptic Ulcer Disease", pages 984-991. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435960B2 (en) | 1998-12-30 | 2013-05-07 | Lakewood-Amedex, Inc. | Devices for improved wound management |
WO2002015844A2 (en) * | 2000-08-23 | 2002-02-28 | Wider Michael D | Antimicrobial composition and methods of use in the treatment of disease |
WO2002015844A3 (en) * | 2000-08-23 | 2002-06-06 | Michael D Wider | Antimicrobial composition and methods of use in the treatment of disease |
US6500861B1 (en) * | 2000-08-23 | 2002-12-31 | Michael D. Wider | Antimicrobial composition and methods of use in the treatment of disease |
JP2009179639A (en) * | 2001-05-03 | 2009-08-13 | Oligos Etc Inc | Antimicrobial compound and method for their use |
CN102088984B (en) * | 2008-07-11 | 2012-08-22 | 万灵杀菌消毒剂股份有限公司 | Eradicating agent and eradication method for helicobacter pylori |
CN108300680A (en) * | 2018-04-18 | 2018-07-20 | 深圳市伯劳特生物制品有限公司 | Helicobacter pylori transports culture medium |
EP3797761A1 (en) * | 2019-09-27 | 2021-03-31 | Eco-Geo Bio-Technology Company Limited | Non-pharmaceutical bactericidal composition against helicobacter pylori |
JP2021052744A (en) * | 2019-09-27 | 2021-04-08 | エコ−ジオ バイオ−テクノロジー カンパニー リミテッド.Eco−Geo Bio−Technology Company Limited. | Non-pharmaceutical bactericidal composition against helicobacter pylori |
Also Published As
Publication number | Publication date |
---|---|
US6071961A (en) | 2000-06-06 |
AU721868B2 (en) | 2000-07-13 |
EP0914040A1 (en) | 1999-05-12 |
JP2001509779A (en) | 2001-07-24 |
CA2238484A1 (en) | 1997-06-05 |
MX9804139A (en) | 1998-09-30 |
AU1141297A (en) | 1997-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6071961A (en) | Antimicrobial composition and methods of use therefor | |
ES2218541T3 (en) | NITRITE ACIDIFIED AS AN ANTIMICROBIAL AGENT. | |
ES2292233T3 (en) | COMPOSITION OF PROPOFOL CONTAINING SULPHITE. | |
US6518307B2 (en) | Control of microbial populations in the gastrointestinal tract of animals | |
US6500861B1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
Lynn Humberston et al. | Ingestion of 35% hydrogen peroxide | |
NZ337080A (en) | Oral preparation containing xanthophylles such as astaxanthin to helicobacter sp.infection | |
EP3618826B1 (en) | Compositions for the treatment of pathogenic infections | |
Hara et al. | Ingestion of guar-gum hydrolysate partially restores calcium absorption in the large intestine lowered by suppression of gastric acid secretion in rats | |
JPH08337538A (en) | Eradicating composition for helicobacter pylori | |
Salim | Use of scavenging oxygen‐derived free radicals to protect the rat against aspirin‐and ethanol‐induced erosive gastritis | |
WO1998013041A1 (en) | Prophylaxis and treatment of intestinal tract fluid and electrolyte loss using histidine compositions | |
CA2217157C (en) | Inhibition of c. difficile infections by indigestible oligosaccharides | |
ES2232195T3 (en) | PARENTERAL SOLUTION OF PROPOFOL (2,6-DIISOPROPILFENOL) AND 2,5-DI-O-METHYL-1,4; 3,6-DIANHYDRO-D-GLUCITOL AS A SOLVENT. | |
Hardin Jr | Caustic burns of the esophagus: A ten-year analysis | |
CN114642631B (en) | Cathartic oral liquid and preparation method thereof | |
JPH06199692A (en) | Agent for amelioration and treatment of cataract | |
CN114712355A (en) | Application of RHPS4 in preparation of medicine for inhibiting human pathogenic bacteria and medicine thereof | |
FR3109299A1 (en) | Combination of artemether and azithromycin in the treatment of epidemics such as Coronavirus. | |
Hotokezaka et al. | Effect of terminal ileal transposition on intestinal absorption following proctocolectomy | |
RU2045266C1 (en) | Cholagogic substance | |
EP0666759A1 (en) | Preparation for therapeutic and especially prophylactic treatment of digestive tract disorders | |
US20050191371A1 (en) | Medical composition | |
Moses et al. | Chronic β-carotene supplementation does not alter the gastric mucosal response to acute aspirin ingestion | |
GB2233899A (en) | Treating gastrointestinal infections with aztreonam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2238484 Country of ref document: CA Ref country code: CA Ref document number: 2238484 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1997 520605 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/004139 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996942811 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97520605 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97520605 Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09077148 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97520605 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996942811 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1997520605 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996942811 Country of ref document: EP |